ACE2 and COVID-19: In order to understand whether CLEC2.Fc had protective effects in SARS‐CoV‐2‐induced thromboinflammation in vivo, we inoculated SARS‐CoV‐2 to the AAV‐ACE2‐infected mice to address this question, as this mouse model mimics the pathophysiology of COVID‐19 patients (Sun et al, 2021).